Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 5, 2005, Pages 1311-1314

  Castle, Philip E ^a   Schiffman, Mark ^a   Scott, David R ^b   Sherman, Mark E ^a   Glass, Andrew G ^b   Rush, Brenda B ^b   Schussler, John E ^c   Wacholder, Sholom ^a   Lorincz, Attila T ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d Digene Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; HYBRIDIZATION; MAJOR CLINICAL STUDY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA PROBES, HPV; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; OREGON; PROSPECTIVE STUDIES; RISK FACTORS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL LOAD;

EID: 18544381256     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0799     Document Type: Article

References (28)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
4. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
5. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
6. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995-3002.
7. Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002;95:2145-51.
8. McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 1984;64:451-8.
9. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994;69:167-71.
10. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Human papillomavirus type 16 in cervical smears as predictor of high-grade cervical intraepithelial neoplasia [corrected]. Lancet 1992;339:959-60.
11. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
12. Wang SS, Hildesheim A. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003;31:35-40.
13. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003;201:1-6.
14. Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr 2003;31:80-8.
15. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;655:2189-93.
16. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-8.
17. van Duin M, Snijders PJ, Schrijnemakers HF, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002;98:590-5.
18. Schlecht NF, Trevisan A, Duarte-Franco E, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003;103:519-24.
19. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228-9.
20. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003;12:477-84.
21. Pretet JL, Dalstein V, Monnier-Benoit S, Delpeut S, Mougin C. High risk HPV load estimated by Hybrid Capture II((R)) correlates with HPV16 load measured by real-rime PCR in cervical smears of HPV16-infected women. J Clin Virol 2004;31:140-7.
22. Castle PE, Lorincz AT, Scott DR, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol 2003;41:4022-30.
23. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
24. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.
25. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.
26. Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 1999;37:1030-4.
27. Sherman ME, Wang SS, Wheeler CM, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 2003;12:1038-44.
28. Scott DR, Hagmar B, Maddox P, et al. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer 2002;96:14-20.